AR037263A1 - Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias - Google Patents

Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias

Info

Publication number
AR037263A1
AR037263A1 ARP020104238A ARP020104238A AR037263A1 AR 037263 A1 AR037263 A1 AR 037263A1 AR P020104238 A ARP020104238 A AR P020104238A AR P020104238 A ARP020104238 A AR P020104238A AR 037263 A1 AR037263 A1 AR 037263A1
Authority
AR
Argentina
Prior art keywords
manufacture
inflammatory
pharmaceutical formulation
prevention
treatment
Prior art date
Application number
ARP020104238A
Other languages
English (en)
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of AR037263A1 publication Critical patent/AR037263A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una formulación farmacéutica que comprende un agonista receptor nucleótido, como ser un disfosfato nucleósido, trifosfato nucleósido, o polifosfato dinucleósido, para la manufactura de un medicamento para prevenir o tratar una enfermedad inflamatoria, que incluye aunque no se limita a, sinusitis, rinitis, conjutivitis, asma, dermatitis, enfermedad del intestino inflamatoria, enfermedades vasculares de colágeno inflamatorias, glomerulonefritis, enfermedades de la piel inflamatorias y sarcoidosis.Las indicaciones preferidas son rinitis alérgica perenne, rinitis alérgica estacional, rinitis alérgica infecciosa y conjuntivitis alérgica Reivindicación 25: Una formulación que comprende un agonista receptor nucleótido para la manufactura de un medicamento para tratar o prevenir una enfermedad inflamatoria.
ARP020104238A 2001-11-06 2002-11-06 Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias AR037263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33782801P 2001-11-06 2001-11-06

Publications (1)

Publication Number Publication Date
AR037263A1 true AR037263A1 (es) 2004-11-03

Family

ID=23322192

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104238A AR037263A1 (es) 2001-11-06 2002-11-06 Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias

Country Status (11)

Country Link
US (1) US7256183B2 (es)
EP (1) EP1450820A4 (es)
JP (1) JP2005532254A (es)
KR (1) KR20050043761A (es)
CN (1) CN1612739A (es)
AR (1) AR037263A1 (es)
BR (1) BR0213897A (es)
CA (1) CA2465894A1 (es)
MX (1) MXPA04004215A (es)
TW (1) TW200300692A (es)
WO (1) WO2003039473A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028712A2 (en) * 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
JPWO2004075906A1 (ja) * 2003-02-26 2006-06-01 リジェンティス株式会社 抗炎症剤及び抗炎症性医療材料
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
SE529064C2 (sv) * 2005-01-03 2007-04-24 Selectica Pharmaceuticals Ab Topiska kompositioner
GB0502250D0 (en) * 2005-02-03 2005-03-09 Ic Vec Ltd Use
US20080227689A1 (en) * 2005-09-29 2008-09-18 Jamey Marth Dampening Humoral and Innate Immunity by Inhibition of Ppgalnact-1
WO2008113072A2 (en) * 2007-03-15 2008-09-18 Board Of Regents, The University Of Texas System Gpcr enhanced neuroprotection to treat brain injury
US8168597B2 (en) * 2008-10-22 2012-05-01 Inspire Pharmaceuticals, Inc. Method for treating cystic fibrosis
GB201209244D0 (en) * 2012-05-25 2012-07-04 Globalacorn Ltd Compositions
US10111904B2 (en) * 2013-01-09 2018-10-30 Berlock Aps Micron-sized gold, kit comprising said gold and its use as a non-toxic immune suppressor
US20150031712A1 (en) * 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
GB201320959D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions
GB201320962D0 (en) * 2013-11-27 2014-01-08 Globalacorn Ltd Compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US6255059B1 (en) 1993-03-31 2001-07-03 Cadus Pharmaceutical Corporation Methods for identifying G protein coupled receptor effectors
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US6147056A (en) * 1995-06-06 2000-11-14 Trustees Of Boston University Use of locally applied DNA fragments
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
US5837861A (en) * 1997-02-10 1998-11-17 Inspire Pharmaceuticals, Inc. Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
JP4271730B2 (ja) 1996-03-27 2009-06-03 インスパイアー ファーマシューティカルズ，インコーポレイティド ウリジン三リン酸及び関連化合物による線毛ジスキネシアの治療方法
US5968913A (en) 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1998015835A1 (en) 1996-10-08 1998-04-16 Inspire Pharmaceuticals, Inc. Method of early lung cancer detection via sputum induction and analysis of sputum to detect cancer associated substances
EP0929218A4 (en) * 1996-10-30 2001-05-16 Univ North Carolina R2Y RECEPTOR ANTAGONISTS
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
ES2264197T3 (es) * 1997-02-06 2006-12-16 Inspire Pharmaceuticals, Inc. Dinucleotidos y sus usos.
JP2001518118A (ja) * 1997-03-25 2001-10-09 アレゲニー ユニバーシティー オブ ザ ヘルス サイエンシズ ヒト肥満細胞活性化のモジュレーション
US6462028B2 (en) 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
JP2001513568A (ja) * 1997-08-29 2001-09-04 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 肺疾患を治療するためのウリジン５’−ジホスフェートとその類似体の使用
AU746750B2 (en) 1998-05-22 2002-05-02 Inspire Pharmaceuticals, Inc. Therapeutic dinucleotide and derivatives
EP1143896B1 (en) * 1998-10-20 2006-12-13 The University of North Carolina at Chapel Hill Methods of hydrating the nasal mucosal surface
AR023088A1 (es) 1999-02-26 2002-09-04 Inspire Pharmaceuticals Inc Uso de disfosfatos de uridina, adenina y citidina y analogos de los mismos para la manufactura de un medicamento para la estimulacion de la hidratacion delas mucosas.
CA2395108A1 (en) * 1999-12-22 2001-06-28 Inspire Pharmaceuticals, Inc. Method of treating gastrointestinal tract disease with purinergic receptor agonists
US6610274B1 (en) * 2000-12-22 2003-08-26 Wallace J. Gardner Anti-inflammatory composition comprising tetracycline
US20040241149A1 (en) * 2001-09-05 2004-12-02 Claudio De Simone Use of unmethylatd cpg

Also Published As

Publication number Publication date
KR20050043761A (ko) 2005-05-11
JP2005532254A (ja) 2005-10-27
US7256183B2 (en) 2007-08-14
TW200300692A (en) 2003-06-16
EP1450820A2 (en) 2004-09-01
WO2003039473A2 (en) 2003-05-15
CA2465894A1 (en) 2003-05-15
BR0213897A (pt) 2006-05-23
MXPA04004215A (es) 2004-07-08
EP1450820A4 (en) 2009-02-18
US20030125299A1 (en) 2003-07-03
WO2003039473A3 (en) 2003-10-23
CN1612739A (zh) 2005-05-04

Similar Documents

Publication Publication Date Title
AR037263A1 (es) Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
UY27939A1 (es) Compuestos
UY27878A1 (es) Derivados de indolinfenilsulfonamida
PE20090942A1 (es) AGENTES ARNi COMO INHIBIDORES DE LA EXPRESION DE ALFA-ENaC
UY31314A1 (es) Amidas heterociclicas y sus métodos de uso-976
UY30015A1 (es) Combinación de antagonista de actividad biológica de angiopoyetina-2 y antagonista de actividad biológica de vegf-a y/o kdr y/o flt1, composiciones farmacéuticas y aplicaciones
PA8603201A1 (es) Procedimiento y composiciones farmaceuticas para el tratamiento de arterosclerosis, dislipidemias y afecciones relacionadas
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
AR035637A1 (es) Betamimeticos de larga accion, procedimiento para su preparacion y su empleo como medicamentos
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
ECSP045115A (es) INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
IS8175A (is) Píperasín afleiður og aðferðir við notkun þeirra
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
UY29092A1 (es) Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
AR046892A1 (es) Suspensiones acuosas de ciclesonida para nebulizaciones y metodo de preparacion
AR034223A1 (es) Novedosa indicacion terapeutica de azitromicina para el tratamiento de enfermedades inflamatorias no infecciosas
AR041942A1 (es) Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria
ES2188801T3 (es) 4-(1h-bencimidazol-2-yl-amino) piperidinas sustituidas utiles para el tratamiento de enfermedades alergicas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure